Streetbeat News

Analyst Ratings

LIVN

Baird analyst David Rescott has upgraded LivaNova (NASDAQ:LIVN) from Neutral to Outperform and increased the price target from $55 to $66.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 11:06 am

OPK

HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on OPKO Health and maintained a $3 price target.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 11:04 am

TIL

HC Wainwright & Co. has reiterated its Buy rating for Instil Bio (NASDAQ:TIL) and maintained a price target of $120, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 11:01 am

KRRO

HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating for Korro Bio (NASDAQ:KRRO) and maintained a $100 price target.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 10:57 am

OB

Needham analyst Laura Martin has reiterated a Buy rating on Outbrain (NASDAQ:OB) and maintained a $6 price target.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 10:53 am

LSCC

Needham analyst Quinn Bolton has reiterated a Buy rating on Lattice Semiconductor (NASDAQ:LSCC) and maintained a price target of $61.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 10:48 am

CGON

HC Wainwright & Co. has reiterated its Buy rating for CG Oncology (NASDAQ:CGON) and maintained a price target of $75, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 10:44 am

PDSB

HC Wainwright & Co. has reiterated its Buy rating on PDS Biotechnology, maintaining a price target of $21. Analyst Joseph Pantginis continues to support the stock's potential.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 10:42 am

CSGP

Needham analyst Mayank Tandon has reiterated a Buy rating on CoStar Group (NASDAQ:CSGP) and maintained a price target of $107.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 10:30 am

ANIP

HC Wainwright & Co. has reiterated its Buy rating on ANI Pharmaceuticals, maintaining a price target of $94. This suggests confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 10:24 am